A research team led by physicians from Dana-Farber Cancer Center are seeing surprising success using the antibody drug conjugate Adcetris against B-cell lymphomas.
In an open-label and ongoing study, researchers recruited more than 60 patients with B-cell non-Hodgkin's lymphomas, with the majority having been diagnosed with the most commonly diagnosed B-cell NHL, diffuse large B-cell lymphoma (DLBCL).
Examining response rate
Among those DLBCL patients, a total of 40 percent had an objective response to the antibody drug conjugate, which is currently only approved for treatment against Hodgkin's lymphoma and anaplastic large T-cell lymphoma. The DLBCL patients had a median duration of 36 weeks; seven of them experienced complete remissions while 10 had partial responses.
These results were surprising since Adcetris works by seeking out the CD30 protein on the cell surface. This protein is only expressed in B-cell tumors about one-third of the time.
Furthermore, investigators discovered that Adcetris appeared to show greater activity in those patients whose tumor only weakly expressed the CD30 protein, which ran counter to all expectations.
Although investigators offered a few hypotheses, they could not explain it.
Source: ASH 2013
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.